Our History

As the pioneers in vacuum-assisted breast biopsy, Mammotome is proud to celebrate over 25 years of innovation.

OVER 25 YEARS OF BREAST CARE INNOVATION

1995

It all began with the Mammotome® Breast Biopsy System. This technology transformed breast cancer intervention from open surgical biopsy to minimally invasive procedures. Originally known as Biopsys, this system provided an accurate diagnosis, while greatly improving the overall patient experience.

1997

Ethicon Endo-Surgery (EES), part of the Johnson & Johnson Family of Companies, acquired Biopsys. EES continued product development on the Mammotome^® biopsy system, expanding the Mammotome brand into the worldwide market leader.

1999

The Mammotome® HH Breast Biopsy System for ultrasound-guided procedures was introduced to the market, a true milestone in the diagnosis of breast lesions.

2001

The Mammotome® ST Breast Biopsy System launched, providing an enhanced biopsy system specifically designed for stereotactic procedures. Mammotome also introduced the MicroMARK II breast biopsy tissue marker.

2004

The Mammotome® system expanded to include Mammotome® EX for ultrasound-guided biopsy procedures. Mammotome also introduced the MammoMARK® line of Biopsy Site Identifiers, designed to enhance performance accuracy in biopsy site marking.

2006

The Mammotome® Breast Biopsy System expanded to include MR for magnetic resonance imaging-guided procedures.

2010

Devicor Medical Products, Inc. acquired the Mammotome breast care business from Ethicon Endo-Surgery.

2011

Devicor Medical Products, Inc. acquired the Neoprobe® Gamma Detection System portfolio of products from Neoprobe Corporation, creating a newly combined breast biopsy and breast surgery portfolio.

2012

In 2012, the Mammotome® Elite Tetherless Vacuum-Assisted Biopsy System launched. The MammoSTAR® Biopsy Site Markers were added to the Mammotome® Markers portfolio, providing an all-natural marking alternative.

2013

Mammotome unveiled the Mammotome Revolve^TM ST Dual Vacuum-Assisted Breast Biopsy System for stereotactic procedures, truly redefining biopsy procedural efficiency without compromising tissue quality.

2014

In 2014, Mammotome greatly expanded its product portfolio. First the launch of the Mammotome Revolve™ U/S Dual Vacuum-Assisted Breast Biopsy System for ultrasound procedures. Two exciting acquisitions including the HydroMARK™ Breast Biopsy Site Marker portfolio and the MammoTest® stereotactic biopsy table. Finally, a distribution agreement was signed for the Faxitron CoreVision in-room specimen radiograph system.

2014

Devicor Medical Products, Inc. was acquired by Leica Biosystems, bringing Mammotome under the Danaher Corporation umbrella.

2017

Mammotome began distributing the Sentimag® Localization Platform, including the Magseed® Magnetic Marker providing wire-free lesion localization. To further expand the Mammotome® Markers portfolio, the company began distributing the all-natural, non-metal BiomarC® Biopsy Site Markers.

2018

Mammotome enters into a distribution agreement with KUB Technologies, Inc. to distribute their line of specimen radiography systems, replacing the Faxitron CoreVision with the Mammotome Confirm^TM Core Specimen Radiography System. The Sentimag® platform expands to include the Magtrace® Lymphatic Tracer, providing radiation-free Sentinel Lymph Node Biopsy.

2020

Mammotome launched the HydroMARK^TM flexible applicators designed to make the clinician’s user experience easier and more intuitive. Mammotome celebrated 25 years of innovation in breast cancer diagnostics. To date, more than 11 million women worldwide have had a successful procedure using a Mammotome breast care solution.¹

^{1. Based on internal sales data}

2022

The Mammotome DualCore^TM Dual Stage Core Biopsy System was launched in the United States and Canada. This core needle device provides another option in the Mammotome ultrasound-guided breast biopsy portfolio.

2023

Mammotome launched the HydroMARK^TM Plus Breast Biopsy Site Marker in the United States, an innovation for tissue marker displacement. The Sentimag® Generation 3 system was enhanced to keep physicians focused on the procedure and not the tools. The Magtrace® tracer received full indication for all breast cancer staging.

2024

Mammotome announced the launch of the LumiMARK™ Biopsy Site Marker in the United States, a tissue marker line designed with visibility top of mind.

^{Products may not be approved or available in your region. Please check with your local Mammotome representative.}

Would you like to know more about our integrated solutions?

Contact Us